This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
by Zacks Equity Research
Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company News for Nov 29, 2021
by Zacks Equity Research
Companies in the news are: ISPC, APVO, VIR, CARS
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (APVO) Outperforming Other Medical Stocks This Year?
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance
5 Stocks to Gain From Dollar's Recent Strength
by Tirthankar Chakraborty
The U.S. dollar hits an almost 2-year record high as global central banks turn dovish and German business moral deteriorates.
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO)
by Zacks Equity Research
Does Aptevo Therapeutics Inc. (APVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.
Emergent Down on '17 View, Posts Preliminary '16 Results
by Zacks Equity Research
Emergent announced better-than-expected preliminary 2016 results. However, the outlook for 2017 fell short of estimates.